Vietnam
· Delayed Price · Currency is VND DBT Statistics
Total Valuation
Ben Tre Pharmaceutical JSC has a market cap or net worth of VND 231.70 billion.
| Market Cap | 231.70B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Ben Tre Pharmaceutical JSC has 18.61 million shares outstanding.
| Shares Outstanding | 18.61M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.14% |
| Owned by Insiders (%) | 35.92% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 13.13.
| PE Ratio | 13.13 |
| Forward PE | n/a |
| PS Ratio | 0.27 |
| PB Ratio | 1.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 1.56.
| Current Ratio | 1.19 |
| Quick Ratio | 0.49 |
| Debt / Equity | 1.56 |
| Debt / EBITDA | 8.93 |
| Debt / FCF | -4.71 |
| Interest Coverage | 1.60 |
Financial Efficiency
Return on equity (ROE) is 8.48% and return on invested capital (ROIC) is 3.38%.
| Return on Equity (ROE) | 8.48% |
| Return on Assets (ROA) | 2.75% |
| Return on Capital (ROIC) | 3.38% |
| Revenue Per Employee | 1.46B |
| Profits Per Employee | 29.85M |
| Employee Count | 566 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 2.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.45% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +14.45% |
| 50-Day Moving Average | 12,416.00 |
| 200-Day Moving Average | 11,416.43 |
| Relative Strength Index (RSI) | 43.28 |
| Average Volume (20 Days) | 19,665 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ben Tre Pharmaceutical JSC had revenue of VND 828.64 billion and earned 16.89 billion in profits. Earnings per share was 948.29.
| Revenue | 828.64B |
| Gross Profit | 199.81B |
| Operating Income | 29.64B |
| Pretax Income | 26.83B |
| Net Income | 16.89B |
| EBITDA | 42.66B |
| EBIT | 29.64B |
| Earnings Per Share (EPS) | 948.29 |
Balance Sheet
The company has 83.16 billion in cash and 380.81 billion in debt, giving a net cash position of -297.65 billion or -15,993.75 per share.
| Cash & Cash Equivalents | 83.16B |
| Total Debt | 380.81B |
| Net Cash | -297.65B |
| Net Cash Per Share | -15,993.75 |
| Equity (Book Value) | 244.79B |
| Book Value Per Share | 10,566.98 |
| Working Capital | 93.28B |
Cash Flow
In the last 12 months, operating cash flow was -74.77 billion and capital expenditures -6.17 billion, giving a free cash flow of -80.94 billion.
| Operating Cash Flow | -74.77B |
| Capital Expenditures | -6.17B |
| Free Cash Flow | -80.94B |
| FCF Per Share | -4,348.95 |
Margins
Gross margin is 24.11%, with operating and profit margins of 3.58% and 2.04%.
| Gross Margin | 24.11% |
| Operating Margin | 3.58% |
| Pretax Margin | 3.24% |
| Profit Margin | 2.04% |
| EBITDA Margin | 5.15% |
| EBIT Margin | 3.58% |
| FCF Margin | -9.77% |
Dividends & Yields
Ben Tre Pharmaceutical JSC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 24.72% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 7.62% |
| FCF Yield | -34.93% |
Stock Splits
The last stock split was on July 5, 2024. It was a forward split with a ratio of 1.14.
| Last Split Date | Jul 5, 2024 |
| Split Type | Forward |
| Split Ratio | 1.14 |
Scores
Ben Tre Pharmaceutical JSC has an Altman Z-Score of 1.67. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.67 |
| Piotroski F-Score | n/a |